Amorepacific deal puts therapeutic target discovery to work on skin aging – and Junevity sees scope for an ‘Ozempic moment’.
San Francisco biotech Junevity is taking its gene-network approach to aging into skincare through a collaboration with Korean beauty and wellness group Amorepacific, applying a platform originally developed for therapeutic target discovery to the search for new cosmetic interventions.
The partnership will use Junevity’s RESET platform to identify transcription factors and pathways involved in skin aging, with Amorepacific then leading the development of cosmetic products designed to act on those targets. Alongside the research collaboration, Amorepacific Ventures has made a strategic investment in Junevity, and Junevity and Amorepacific have signed a separate licensing agreement covering cosmetic applications.
Longevity.Technology: The beauty industry has become increasingly comfortable borrowing the language of longevity; what makes this collaboration rather more interesting is that it is borrowing some of the biology too. Junevity’s RESET platform was built not to make aging cells look better, but to interrogate the gene networks that help make them old in the first place – and bringing that target-first approach into skincare shifts the proposition from finding an ingredient and explaining what it does to identifying an aging mechanism, then asking how it might be modulated. That is an important distinction, although perhaps also an inconvenient one for an industry in which rejuvenation has traditionally enjoyed rather more freedom as a marketing term than as a biological claim. If RESET-derived cosmetic interventions can do more than improve hydration, elasticity or the appearance of wrinkles – if they can produce coherent changes in gene expression, molecular measures of aging and tissue function – then this begins to look less like longevity-themed skincare and more like an accessible experiment in whether aspects of human tissue aging can actually be reset. Skin, being visible, repeatedly measurable and unusually amenable to sampling, is an obliging place to try; it may also prove an unforgiving place to discover exactly how much weight the word rejuvenation can bear.
A therapeutic engine in the cosmetics lab
RESET combines human disease omics, genetic linkages and ML/AI to identify transcription factors whose modulation could alter wider gene networks. Junevity’s therapeutic strategy uses siRNA to repress such targets, with an obesity candidate heading into human clinical trials; the skincare program takes a different route, with pathways surfaced by the same discovery engine handed to Amorepacific to translate into cosmetic products.
“Through the RESET platform, we dissect the genetic and transcriptomic networks underlying human skin aging to uncover the genes and pathways driving it,” Junevity cofounder and CSO Dr Janine Sengstack told Longevity.Technology. “For this collaboration leveraging Amorepacific’s deep expertise in cosmetics, we are identifying pathways that can lead to a transcriptional reset and skin aging benefits.”
The scientific premise builds on Sengstack’s work at UCSF, notably peer-reviewed research published in PNAS in January showing that modulation of individual transcription factors could reverse hallmarks of cellular aging in experimental models, including those of aging in human fibroblasts – cells with a central role in skin structure and repair. In such models, Sengstack said, repressing a single transcription factor could “restore aged cells toward a healthier state”; the collaboration is, in effect, a bet that so small a lever can shift something as complex as aging skin.
From appearance to biological age
For a cosmetic program, the evidentiary question is unusually interesting. Conventional endpoints such as wrinkle appearance, hydration or elasticity can establish a useful product effect without demonstrating that the underlying tissue has become biologically younger. Sengstack said the collaboration intends to look deeper.
“This work goes beyond improvement in conventional cosmetic endpoints and aims to reprogram the skin back to that younger, healthier state,” she said. “We expect to see improvements in collagen and elastin as well as global gene expression and aging clocks.”
Those measures will need careful interpretation; after all, aging clocks are biomarkers rather than verdicts on rejuvenation, while movement in gene expression does not by itself establish durable reversal of an aging phenotype. However, combining molecular readouts with functional and structural endpoints could make skin a particularly tractable tissue in which to examine whether a transcriptional reset translates into something biologically meaningful.
An accessible testbed
That accessibility may matter beyond cosmetics. Skin can be sampled repeatedly, treated locally and observed over time – advantages rarely available when interrogating aging biology in internal organs. Asked whether skin could become a useful human testbed for resetting gene networks, Sengstack was emphatic, agreeing “absolutely”.
“We believe there is the opportunity for an ‘Ozempic moment’ in skin rejuvenation and longevity,” she told Longevity.Technology. “Junevity’s other RESET therapeutic programs have already demonstrated in vivo that resetting gene expression can drive the reversal of disease. This collaboration with Amorepacific is an exciting test case for resetting gene networks and skin rejuvenation.”
Amorepacific, founded in 1945 and active across skincare, makeup, haircare, inner beauty and beauty technology, will lead product development and commercialization following target discovery and validation. Junevity, meanwhile, will continue developing therapeutic applications of RESET.
“The next generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin aging, particularly the role of gene networks and transcriptional regulation in longevity,” said Brian Byung-Fhy Suh, CTO of Amorepacific R&I Center.
Where the skin leads
There is considerable distance between identifying an aging-associated transcriptional network and putting a product on a bathroom shelf that meaningfully alters it. That distance is precisely what makes this collaboration worth watching. If skin can provide a relatively accessible human proving ground for interventions derived from geroscience, the lessons may travel further than cosmetics – skin deep, for once, could be quite deep enough.
